A diagnostics company has agreed to stop selling two questionable blood tests as part of a settlement with a consumer watchdog that accused the firm of using “false and misleading advertising” to promote the products.
Not only was EpicGenetics claiming that one of its blood tests could definitively diagnose fibromyalgia, the Center for Science in the Public Interest’s October 2023 lawsuit said; the company had also invented a disease wholesale to justify the use of another product, and had dangled nonexistent treatment trials as an enticement for patients.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
